Expression of SEC62 Oncogene in Benign, Malignant and Borderline Melanocytic Tumors—Unmasking the Wolf in Sheep’s Clothing?

By C. Müller, C. Pföhler, M. Wahl, F. Bochen, S. Körner, J. Kühn, A. Bozzato, B. Schick, Maximilian Linxweiler. 2021

Subfields: Dermatology, Oncology, Pathology and Forensic Medicine

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Knebel
2. Maximilian Linxweiler
3. S. Körner
4. L. Brust
5. Matthias Schneider
6. F. Braun
7. S. Wemmert
8. J. Kühn

Citations in the corpus

• Expression of 3q Oncogene SEC62 Predicts Survival in Head and Neck Squamous Cell Carcinoma Patients Treated with Primary Chemoradiation (2023, background): “…in HNSCC [22], melanoma [23], breast cancer [24], and non-small cell lung cancer (NSCLC [25,26]), advanced lymph node metastasis in NSCLC [25], melanoma [23], gastric cancer [27], colorectal cancer [28], and HNSCC [22], as well as distant metastasis in breast cancer [24] and melanoma [23].”